Anixa Biosciences (NASDAQ:ANIX) Raised to “Hold” at Wall Street Zen

Anixa Biosciences (NASDAQ:ANIX – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts have also issued reports on ANIX. Weiss Ratings raised Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. HC Wainwright dropped their target price on Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. Zacks Research downgraded Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.00.

View Our Latest Research Report on ANIX

Anixa Biosciences Trading Down 6.2%

Shares of NASDAQ:ANIX opened at $2.44 on Friday. Anixa Biosciences has a 12 month low of $2.32 and a 12 month high of $5.46. The company has a 50-day moving average price of $2.85 and a 200 day moving average price of $2.95. The company has a market cap of $84.81 million, a price-to-earnings ratio of -7.62 and a beta of 0.47.

Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last released its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). As a group, equities analysts forecast that Anixa Biosciences will post -0.31 EPS for the current year.

Insider Activity

In other news, Director Lewis Titterton, Jr. bought 49,036 shares of the stock in a transaction dated Wednesday, September 23rd. The stock was purchased at an average price of $2.69 per share, for a total transaction of $131,906.84. Following the acquisition, the director owned 1,046,003 shares of the company’s stock, valued at $2,813,748.07. The trade was a 4.92% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have bought 105,536 shares of company stock valued at $291,587. 26.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Anixa Biosciences during the second quarter valued at approximately $559,000. AXQ Capital LP bought a new position in shares of Anixa Biosciences during the second quarter valued at approximately $41,000. Corient Private Wealth LP bought a new position in shares of Anixa Biosciences during the second quarter valued at approximately $105,000. Canada Pension Plan Investment Board purchased a new stake in shares of Anixa Biosciences in the second quarter worth approximately $38,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Anixa Biosciences in the second quarter worth approximately $29,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc. is a U.S.-based biotechnology company focused on developing cancer immunotherapies. Its research programs include a CAR T-cell therapy designed to target ovarian cancer and cancer vaccine candidates developed with research partners. The company’s ovarian cancer program uses T cells engineered to recognize follicle-stimulating hormone receptors on cancer cells and is being developed in collaboration with Moffitt Cancer Center. Anixa is also working with Cleveland Clinic on a breast cancer vaccine program intended to stimulate an immune response against cancer-related targets.

Further Reading

Analyst Recommendations for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.